OS THERAPIES INCORPORATED Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
OS THERAPIES INCORPORATED (OSTX) had Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net of $0 as of 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Debt › Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet · last filed 2026-03-31
- 2025-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $0.00.
- 2025-09-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $0.00.
- 2025-06-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $0.00.
- 2025-03-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $0.00.
| Period end | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-31 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-14 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-18 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-15 |
| 2024-12-31 | $0.00 10-Q · filed 2025-08-18 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-15 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-14 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-20 |
| 2023-12-31 | $49.84K 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |